ASCVD
Tourmaline Attracted Bidding War Before $1.4B Acquisition by Novartis
Tourmaline Bio; Novartis; acquisition; bidding war; $1.4 billion; pacibekitug; cardiovascular drug; IL-6 antibody; ASCVD; biotech
Actionable Insights Powered by AI
Tourmaline Bio; Novartis; acquisition; bidding war; $1.4 billion; pacibekitug; cardiovascular drug; IL-6 antibody; ASCVD; biotech